Acutaas Chemicals Ltd Hits All-Time High, Marking a Milestone in Market Performance

2 hours ago
share
Share Via
Acutaas Chemicals Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, reached a new all-time high of Rs. 2208.15 today, underscoring its robust market performance and sustained growth trajectory over recent years.
Acutaas Chemicals Ltd Hits All-Time High, Marking a Milestone in Market Performance

Record-Breaking Price Movement

On 4 Mar 2026, Acutaas Chemicals Ltd achieved a fresh 52-week high, closing at Rs. 2208.15. Despite a day’s decline of 3.09%, the stock’s milestone reflects a significant appreciation from its levels a year ago. The stock opened with a gap down of 2.5%, touching an intraday low of Rs. 2119.8 (-3.26%), yet it remains comfortably above its key moving averages, including the 20-day, 50-day, 100-day, and 200-day averages, signalling sustained underlying strength. However, it currently trades slightly below its 5-day moving average, indicating some short-term consolidation.

Comparative Performance Against Benchmarks

Acutaas Chemicals Ltd has outperformed the broader market indices and its sector peers over multiple time horizons. The stock’s one-year return stands at an impressive 86.26%, vastly exceeding the Sensex’s 7.60% gain over the same period. Year-to-date, the stock has appreciated by 24.68%, while the Sensex has declined by 7.84%. Over the past three months, the stock surged 24.10%, contrasting with the Sensex’s 7.89% fall. Even on a weekly basis, Acutaas Chemicals Ltd’s performance of -1.92% outpaces the Sensex’s -4.54% decline, demonstrating resilience amid broader market volatility.

Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!

  • - Fresh momentum detected
  • - Explosive short-term signals
  • - Early wave positioning

Catch the Wave Now →

Strong Fundamentals Underpinning Growth

Acutaas Chemicals Ltd’s ascent to its all-time high is supported by solid financial metrics and operational efficiency. The company boasts a low average Debt to Equity ratio of zero, reflecting a debt-free capital structure that reduces financial risk. Net sales have grown at a compounded annual rate of 26.84%, while operating profit has expanded at an even stronger rate of 38.56%, signalling effective cost management and margin improvement.

Net profit growth has been particularly remarkable, increasing by 47.82% in the latest reported period ending December 2025. This marks the sixth consecutive quarter of positive results, highlighting consistent earnings momentum. The company’s Return on Capital Employed (ROCE) for the half-year period stands at a robust 21.30%, indicating efficient utilisation of capital to generate profits.

Operational efficiency is further demonstrated by the highest inventory turnover ratio of 5.74 times and a debtors turnover ratio of 3.76 times for the half-year, reflecting effective working capital management and strong collection processes.

Institutional Confidence and Market Recognition

Institutional investors hold a significant 38.38% stake in Acutaas Chemicals Ltd, signalling confidence from entities with extensive analytical resources. The company is ranked among the top 1% of all 4,000 stocks rated by MarketsMojo, securing the 6th position among small-cap stocks and 18th across the entire market. Its Mojo Score of 82.0 earned it an upgrade from a Buy to a Strong Buy rating on 6 Oct 2025, reflecting improved quality and growth prospects.

Market Capitalisation and Valuation Metrics

The company holds a Market Cap Grade of 3, indicating a mid-sized market capitalisation within its sector. Despite its strong growth, Acutaas Chemicals Ltd carries a premium valuation, with a Price to Book Value ratio of 12.7 and a Return on Equity (ROE) of 15.8%. The PEG ratio of 0.5 suggests that earnings growth is outpacing the valuation premium, which may be a factor in the stock’s elevated price levels.

Acutaas Chemicals Ltd caught your attention? Explore our comprehensive research report with in-depth analysis of this small-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!

  • - Comprehensive research report
  • - In-depth small-cap analysis
  • - Valuation assessment included

Explore In-Depth Research →

Long-Term Performance and Sector Context

Over a three-year horizon, Acutaas Chemicals Ltd has delivered a staggering 354.57% return, vastly outperforming the Sensex’s 31.32% gain. This market-beating performance extends to shorter periods as well, with the stock outperforming the BSE500 index over one year and three months. The company operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed performance recently, making Acutaas Chemicals Ltd’s strong returns particularly noteworthy.

Short-Term Price Dynamics

Despite the all-time high, the stock underperformed its sector by 2.66% on the day of the record price, reflecting some profit-taking or short-term volatility. The one-day performance of -3.09% was slightly worse than the Sensex’s -2.12% decline, indicating that the stock is undergoing a brief correction after its strong rally. Nonetheless, the longer-term trend remains firmly positive.

Summary of Key Financial Metrics

To summarise, Acutaas Chemicals Ltd’s key financial highlights include:

  • Net Sales growth at 26.84% CAGR
  • Operating Profit growth at 38.56% CAGR
  • Net Profit growth of 47.82% in the latest period
  • ROCE at 21.30% (half-year)
  • Inventory Turnover Ratio at 5.74 times (half-year)
  • Debtors Turnover Ratio at 3.76 times (half-year)
  • Debt to Equity ratio averaging zero
  • Institutional holdings at 38.38%
  • Mojo Score of 82.0 with a Strong Buy grade

These metrics collectively illustrate a company with strong growth, efficient capital management, and solid market recognition.

Conclusion

Acutaas Chemicals Ltd’s achievement of a new all-time high at Rs. 2208.15 marks a significant milestone in its market journey. Supported by robust financial performance, strong institutional backing, and consistent earnings growth, the company has demonstrated resilience and strength within the Pharmaceuticals & Biotechnology sector. While short-term price fluctuations are evident, the long-term trend remains decisively positive, reflecting the company’s ability to generate substantial shareholder value over time.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News